Abstract
Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1−/− mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1−/− ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.
Footnotes
-
↵1 P.P. is on leave from the Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungry. L.L. is on leave from the Critical Care Division, Department of Internal Medicine, University Hospital, Lausanne, Switzerland.
-
This work was supported by a grant from the National Institutes of Health (R01HL 59266) to C.S. P.B. was supported by TeT Foundation fellowship 27/MO/01 and L.V. by Grant OTKA T035182 and Bolyai Scholarship of Hungarian Academy of Sciences.
- Abbreviations:
- PARP
- poly(ADP-ribose) polymerase
- PARS
- poly(ADP-ribose) synthetase
- DOX
- doxorubicin
- +dp/dt
- maximal slope of systolic pressure increment
- −dp/dt
- maximal slope of diastolic pressure decrement
- LDH
- lactate dehydrogenase
- CK
- creatine kinase
- MMP
- metalloproteinase
- Received October 7, 2001.
- Accepted November 27, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|